Liver Function Test Abnormalities and Pruritus in a Patient Treated with Atorvastatin: Case Report and Review of the Literature

Pharmacotherapy

Volumn 24, Issue 1, 2004, Pages 150-154

  Gershovich, Olga E ^a   Lyman Jr , Alfred E ^a  

^a Clinical Pharmacy Services   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitor; Alanine aminotransferase; Atorvastatin; Hepatotoxicity; Liver function test; Statin; Transaminase

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; DRUG ACTIVITY; FEMALE; HUMAN; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; POSTMARKETING SURVEILLANCE; PRURITUS; SYMPTOMATOLOGY;

ADMINISTRATION, ORAL; AGED; ALANINE TRANSAMINASE; DRUG MONITORING; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LIVER; LIVER FUNCTION TESTS; PRURITUS; PYRROLES;

EID: 0347988040     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.1.150.34803     Document Type: Article

References (14)

1. Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Safety 2000;23:197-213.
2. Pfizer Inc. Lipitor (atorvastatin calcium) tablets package insert. Revised April 2002.
3. Tolman KG. The liver and lovastatin. Am J Cardiol 2002;89: 1374-80.
4. Roberts WC. Getting more people on statins. Am J Cardiol 2002;90:683-5.
5. Jellin JM, Gregory PJ, Batz F, et al. Pharmacist's letter/prescriber's letter/natural medicines comprehensive database, 5th ed. Stockton, CA: Therapeutic Research Faculty. Available from http://www.NaturalDatabase.com. Accessed February 5, 2002.
6. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med 1998;158:577-84.
7. Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet 1999;353:1763-4.
8. van Dam M, Zwart M, de Beer F, et al. Long-term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia. Heart 2002;88;234-8.
9. Insull W Jr, for the ASSET Investigators. The efficacy and safety of atorvastatin versus simvastatin in mixed dyslipidemic patients with type 2 diabetes during 54 week [abstr]. Diabetes 2001;50(suppl 2):143a.
10. Karalis DG, Ross AM, Vacari RM, Zarren H, Scott R, for the CHALLENGE Study Investigators. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol 2002;89:667-71.
11. Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997;80:39-44.
12. Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol 1997;79:1475-81.
13. Bakker-Arkema RG, Nawrocki JW, Black DM. Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. Atherosclerosis 2000;149:123-9.
14. Jimenez-Alonzo J, Osorio JM, Gutierrez-Cabello F, de la Osa AL, Leon L, Garcia JDM. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Arch Intern Med 1999;159:1811-12.